Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tagrisso before definitive radiotherapy in EGFR-mutant stage IIIA/IIIB NSCLC
MOH_2018-08-23_003565Phase 2Not yet recruiting
- Sponsor
- פרופ' ניר פלד
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by פרופ' ניר פלד. Primary endpoint: Not reported. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2018-08-23_003565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-08-23_003565.